glycosyl antigen CA199

The glycosyl antigen CA199 is a mucin-type saccharide protein tumor marker, which is a glycolipid on the cell membrane and is named for recognition by the murine monoclonal antibody 116NS19-9. It is the most sensitive marker for pancreatic cancer reported so far. In serum it exists in the form of salivary mucin, which is distributed in the normal fetal pancreas, gallbladder, liver, intestine, and normal adult pancreas, bile duct epithelium, and the like. It is a tumor-associated antigen of the gastrointestinal tract that exists in the blood circulation. Basic Information Specialist classification: inspection classification: immune examination Applicable gender: whether men and women apply fasting: fasting Analysis results: Below normal: Normal value: no Above normal: negative: normal. Positive: CA199 is used as a diagnostic and differential indicator for pancreatic cancer and cholangiocarcinoma. 80%-90% of patients with pancreatic cancer have a significant increase in blood CA199. Patients with liver cancer, gastric cancer, esophageal cancer, and partial cholangiocarcinoma also showed an increase. Preoperative CA199 levels were associated with prognosis. Assuming that the result is greater than 37 IU/ml does not mean that the subject is abnormal, and it is not possible to diagnose the subject as a cancer patient. The increase in low concentration and transient increase can be seen in biliary obstruction, cholecystitis, cholangitis, cirrhosis, Acute and chronic pancreatitis. It is recommended that for patients who are positive for initial testing, dynamic monitoring of changes in values ​​is required (for periodic review, the same detection system must be used). Tips: Inappropriate people: CA19-9 is not suitable for screening tumors in the population. Normal value Serum <37 U/ml. Clinical significance Abnormal results: CA199 is a diagnostic and differential indicator for pancreatic cancer and cholangiocarcinoma. 80%-90% of patients with pancreatic cancer have a significant increase in blood CA199. Patients with liver cancer, gastric cancer, esophageal cancer, and partial cholangiocarcinoma also showed an increase. Preoperative CA199 levels were associated with prognosis. Assuming that the result is greater than 37 IU/ml does not mean that the subject is abnormal, and it is not possible to diagnose the subject as a cancer patient. The increase in low concentration and transient increase can be seen in biliary obstruction, cholecystitis, cholangitis, cirrhosis, Acute and chronic pancreatitis. It is recommended that for patients who are positive for initial testing, dynamic monitoring of changes in values ​​is required (for periodic review, the same detection system must be used). People who need to be examined: patients with pancreatic cancer, hepatobiliary cancer, stomach cancer, and colorectal cancer. The diet is often irregularly scheduled, and the elderly should be regularly tested. Positive results may be diseases: liver cirrhosis, cholecystitis, stomach cancer, pancreatic cancer, colorectal cancer considerations Taboo before the test: Do not eat too greasy food and alcohol the night before the blood is taken, so as not to affect the results of the medical examination. Requirements for examination: CA199 is checked once before surgery, every 3 months in the first year after surgery, every 6 months in the second year, and once every year. If any indicator rises during the examination, Patients are required to check every 3 months. Inspection process The detection principle of CA199 reagent: increase the concentration of coated antibody, reduce the pH value of the matrix, and use F(Ab')2 as the labeled antibody. The above design can amplify the detection signal. The measurement of CA19-9 is usually carried out by immunoradiometric assay (IRMA), enzyme-linked immunosorbent assay (ELISA), chemiluminescence and electrochemiluminescence immunoassay (CLlA and ECLIA). Not suitable for the crowd Inappropriate population: CA19-9 is not suitable for screening tumors in the population, and its serum level can not be used as absolute evidence of whether there is a tumor. The judgment of the results should be combined with clinical and other examinations. Adverse reactions and risks It is a safe check and is harmless to the body.